846 related articles for article (PubMed ID: 15944250)
1. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.
Lugade AA; Moran JP; Gerber SA; Rose RC; Frelinger JG; Lord EM
J Immunol; 2005 Jun; 174(12):7516-23. PubMed ID: 15944250
[TBL] [Abstract][Full Text] [Related]
2. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity.
Lugade AA; Sorensen EW; Gerber SA; Moran JP; Frelinger JG; Lord EM
J Immunol; 2008 Mar; 180(5):3132-9. PubMed ID: 18292536
[TBL] [Abstract][Full Text] [Related]
3. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
Zhang X; Niedermann G
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
[TBL] [Abstract][Full Text] [Related]
4. Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.
Stoitzner P; Green LK; Jung JY; Price KM; Atarea H; Kivell B; Ronchese F
Cancer Immunol Immunother; 2008 Nov; 57(11):1665-73. PubMed ID: 18311487
[TBL] [Abstract][Full Text] [Related]
5. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
[TBL] [Abstract][Full Text] [Related]
6. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL.
Nelson DJ; Mukherjee S; Bundell C; Fisher S; van Hagen D; Robinson B
J Immunol; 2001 May; 166(9):5557-66. PubMed ID: 11313395
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
8. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
[TBL] [Abstract][Full Text] [Related]
9. In vivo augmentation of tumor-specific CTL responses by class I/peptide antigen complexes on microspheres (large multivalent immunogen).
Goldberg J; Shrikant P; Mescher MF
J Immunol; 2003 Jan; 170(1):228-35. PubMed ID: 12496404
[TBL] [Abstract][Full Text] [Related]
10. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
11. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice.
Garcia-Hernandez Mde L; Hamada H; Reome JB; Misra SK; Tighe MP; Dutton RW
J Immunol; 2010 Apr; 184(8):4215-27. PubMed ID: 20237297
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
Sharabi AB; Nirschl CJ; Kochel CM; Nirschl TR; Francica BJ; Velarde E; Deweese TL; Drake CG
Cancer Immunol Res; 2015 Apr; 3(4):345-55. PubMed ID: 25527358
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
[TBL] [Abstract][Full Text] [Related]
14. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
Palmer DC; Balasubramaniam S; Hanada K; Wrzesinski C; Yu Z; Farid S; Theoret MR; Hwang LN; Klebanoff CA; Gattinoni L; Goldstein AL; Yang JC; Restifo NP
J Immunol; 2004 Dec; 173(12):7209-16. PubMed ID: 15585842
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
16. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
17. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
[TBL] [Abstract][Full Text] [Related]
18. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
19. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
20. Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells.
Liao YP; Wang CC; Butterfield LH; Economou JS; Ribas A; Meng WS; Iwamoto KS; McBride WH
J Immunol; 2004 Aug; 173(4):2462-9. PubMed ID: 15294960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
